18
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Reduction of Circulating Secretory Phospholipase A2 Levels by Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody in Patients with Severe Crohn's Disease

Pages 1094-1098 | Published online: 08 Jul 2009

References

  • Van den Bosch H. Intracellular phospholipase A2. Biochem Biophys Acta 1980;604:101–46.
  • Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia [review]. Crit Care Med 1993;21:1376–86.
  • Larsen GL, Henson PM. Mediators of inflammation. Rev Immunol 1983;1:335–59.
  • Irvine RF. How is the level of free arachidonic acid controlled in mammalian cells? Biochem J 1982;204:3–16.
  • Vadas P, Pruzanski W. Induction of group II phospolipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993;39:160–7.
  • Vadas P. Plasma phospholipase A2 levels correlate with the hemodynamic and pulmonary changes in gram negative shock in man. J Lab Clin Med 1984;104:873–81.
  • Pruzanski W, Vadas P, Stefanski E, Urowitz MB. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. J Rheumatol 1985;12:211–16.
  • Pruzanski W, Keystone EC, Sternby B, Bombardier C, Snow HM, Vadas P. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J Reumatol 1988;14:1351–55.
  • Vadas P, Taylor TE, Chimsuku L, Goldring D, Stefanski E, Pruzanski W, et al. Increased serum phospholipase A2 activity in Malawian children with falciparum malaria. Am J Trop Med Hyg 1993;49:455–9.
  • Rintala EM, Nevalainen TJ. Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 1993;17:864–70.
  • Nevalainen TJ. The role of phospholipase A2 in acute pancreatitis. Scand J Gastroenterol 1980;15:641–50.
  • Minami T, Tojo H, Shinomural Y. Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn’s disease and ulcerative colitis. Gut 1992;33: 914–21.
  • Vadas P, Pruzanski W, Kim J, Fornasier V. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am J Pathol 1989;134:807–11.
  • Chang J, Gilman SC, Lewis AJ. Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL-1 action. J Immunol 1989;136: 1283–87.
  • Vadas P, Pruzanski W. Role of secretory phospholipase A2. Lab Invest 1986;55:391–404.
  • Nevalainen TJ, Kortesuo PT, Rintala E, Marki F. Immunochemical detection of group I and group II phospholipases A2 in human serum. Clin Chem 1992;38:1824–29.
  • Rintala EM, Nevalainen TJ. Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy. Eur J Haematol 1993;50:11–16.
  • Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991;266: 2647–51.
  • Pruzanski W, Vadas P. Phospholipase A2—a mediator between proximal and distal effectors of inflammation. Immunol Today 1991;12:143–6.
  • Glaser KB, Mobilio D, Chang JY, Senko N. Phospholipase A2 enzymes: regulation and inhibition. TiBS 1993;14:92–8.
  • Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn’s disease and ulcerative colitis. Gut 1994; 35:1593–8.
  • Minami T, Tojo H, Shinomura Y, Komatsubara T, Matsuzawa Y, Okamoto M. Elevation of phospholipase A2 protein in sera of patients with Crohn’s disease and ulcerative colitis. Am J Gastroenterol 1993;88:1076–80.
  • Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89–91.
  • MacDonald TT, Hutchings P, Choy M, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301–5.
  • Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio PWS, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of childeren with inflammatory bowel disease. Gastroenterology 1994;106:1455–66.
  • van der Poll T, Buller HR, Ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622–7.
  • van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Buller HR, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992;79:693–8.
  • van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn’s disease with an anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–35.
  • Smith GM, Ward RL, McGuian L, Rajkovic IA, Scott KF. Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheum 1992; 31:175–8.
  • Pruzanski W, Stepfanski E, Wilmore DW, Martich GD, Hoffman AGD, Suffredini A. Sequential activation of TNF-phospholipase axis following I.V. endoxin challenge in human volunteers. FASEB J 1990;4:A1714.
  • Pruzanski W, Mackensen A, Engelhardt R, Stefanski E, Vadas P. Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunother 1992;12: 242–6.
  • Pruzanski W, Wilmore DW, Suffredini A, Martich GD, Hoffman AGBJ, Stefanski E, et al. Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin. Inflammation 1992;16:561–70.
  • Pruzanski W, Sherman ML, Kufe DW, Vadas P. Hyperphosphalipasemia A2 following I.V. infusions of tumor necrosis factor in man. Blood 1990;76:A3839.
  • Vadas P, Pruzanski W, Farewell V. A predictive model of soluble phospholipase A2 during septic shock. J Lab Clin Med 1991;118: 471–5.
  • Barbour SE, Dennis EA. Antisense inhibitions of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388D1 cells. J Biol Chem 993;268: 21875–82.
  • Fonteh AN, Bass DA, Marshall LA, Seeds M, Samet JM, Chilton FH. Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol 1994;152:5438–46.
  • Hoffmann GE, Hiefinger R, Steinbrueckner B. Serum phospholipase A2 in hospitalized patients. Clin Chim Acta 1989;183: 59–64.
  • Hoffmann GE, Guder WG. Serum phospholipase: regulatory and pathophysiological aspects. Klin Wochenschr 1989;67:144–8.
  • Elsbach P, Weiss J. Phagocytosis of bacteria and phospholipid degradation. Biochem Biophys Acta 1988;947:29–52.
  • Weiss J, Inada M, Elsbach P, Crowl RM. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994;269:26331–7.
  • Inada M, Crowl RM, Bekkers ACAPA, Verheij H, Weiss J. Determinants of inhibitory action of purified 14-kDa phospholipases A2 on cell-free prothrombinase complex. J Biol Chem 1994;42: 26338.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.